恶性肿瘤伤口患者伤口症状生活困扰的变化轨迹及影响因素研究

doi:10.3761/j.issn.1672-9234.2022.07.014

摘要/Abstract

摘要：

目的了解恶性肿瘤伤口患者确诊后不同时间的伤口症状对其生活困扰水平的变化轨迹,并探究其影响因素。方法采用纵向研究设计,分别在106例患者病理确诊时（T1）、诊断后1个月（T2）、诊断后3个月（T3）、诊断后6个月（T4）评估其伤口症状生活困扰水平,比较不同治疗阶段伤口症状生活困扰水平差异并分析其影响因素。结果伤口症状生活困扰得分T1（49.20±13.78）分、T2（57.71±13.47）分、T3（45.58±13.69）分、T4（43.79±12.98）分。治疗阶段、性别、伤口渗液、伤口气味、伤口瘙痒和换药频率是伤口症状生活困扰的影响因素。结论恶性肿瘤伤口患者伤口症状生活困扰水平呈现先升高后降低的变化趋势,应加强恶性肿瘤伤口患者的早期评估、持续追踪和全程症状管理,降低其伤口症状生活困扰水平。

关键词: 纵向研究, 影响因素分析, 恶性肿瘤伤口, 症状生活困扰

Abstract:

Objective To understand the change trajectory and influencing factors of wound symptom distress at different times after the diagnosis of malignant tumor wound. Methods A longitudinal study design was used to evaluate patients’ wound symptom distress at the time of pathological diagnosis （T1）,1 month after diagnosis （T2）,3 months after diagnosis（T3）,and 6 months after diagnosis （T4）. The distress in different periods was compared and the influencing factors of symptom distress were analyzed. Results The wound Symptom Intrusiveness score：T1 （49.20±13.78）,T2 （57.71±13.47）,T3 （45.58±13.69）,and T4 （43.79±12.98）. Treatment stage,gender,wound exudation,wound odor,wound pruritus and dressing change frequency were the influencing factors of wound symptoms distress. Conclusion The trajectory of wound symptom distress in patients with malignant fungating wounds firstly going high then becoming low. Early evaluation,continuous follow-up and whole process symptom management of patients with malignant fungating wounds should be strengthened to reduce wound symptoms and improve the quality of life of patients.

Key words: Longitudinal Studies, Root Cause Analysis, Malignant Fungating Wounds, Symptom intrusiveness

刘鑫,林桦,张婷,沈玲. 恶性肿瘤伤口患者伤口症状生活困扰的变化轨迹及影响因素研究[J]. 中华护理教育, 2022, 19(7): 652-656.

LIU Xin,LIN Hua,ZHANG Ting,SHEN Ling. A longitudinal study on the change trajectory and influencing factors of wound symptom distress in patients with malignant fungating wounds[J]. Chinese Journal of Nursing Education, 2022, 19(7): 652-656.

图/表 3

参考文献 16

[1]	Grocott P, Gethin G, Probst S. Malignant wound management in advanced illness:new insights[J]. Curr Opin Support Palliat Care, 2013, 7(1):101-105. doi: 10.1097/SPC.0b013e32835c0482
[2]	American Cancer Society. Cancer Facts and Figures[EB/OL].(2017-12-22).https://www.cancer.org/research/cancer-facts-statis-tics/all-cancer-facts-figures/cancer-facts-figures-2017.html .
[3]	Tilley CP, Fu MR, Qiu JM,et al. The microbiome and meta-bolome of malignant fungating wounds[J]. J Wound Ostomy Cont Nurs, 2021, 48(2):124-135.
[4]	Tandler S, Stephen-Haynes J. Fungating wounds:management and treatment options[J]. Br J Nurs, 2017, 26(12 Suppl):S6-S14.
[5]	Tilley C, Lipson J, Ramos M. Palliative wound care for malignant fungating wounds:holistic considerations at end-of-life[J]. Nurs Clin North Am, 2016, 51(3):513-531. doi: 10.1016/j.cnur.2016.05.006
[6]	Monfre JM, Kelechi TJ, Magwood GS,et al. Development and psychometric evaluation of the symptom intrusiveness rating scale among individuals experiencing pain associated with chronic wounds[J]. J Wound Ostomy Continence Nurs, 2015, 42(5):474-479. doi: 10.1097/WON.0000000000000160
[7]	李孟喜, 柏素萍, 魏青. 中文版症状生活干扰评估量表在慢性伤口疼痛患者中的信效度检验[J]. 中国实用护理杂志, 2018, 34(31):2414-2417.
	Li MX, Bai SP, Wei Q. Reliability and validity of Chinese version of Symptom Intrusiveness Rating Scale among patients experiencing pain associated with chronic wound[J]. Chin J Pract Nurs, 2018, 34(31):2414-2417.
[8]	Naylor W. Symptom control in the management of fungating wounds[EB/OL].[2020-11-02]. http://www.worldwidewounds.com/2002/march/Naylor/Symptom-Control-Fungating-Wounds.html .
[9]	Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale[J]. Pain, 1983, 16(1):87-101. doi: 10.1016/0304-3959(83)90088-X pmid: 6602967
[10]	Lo SF, Hu WY, Hayter M,et al. Experiences of living with a malignant fungating wound:a qualitative study[J]. J Clin Nurs, 2008, 17(20):2699-2708. doi: 10.1111/j.1365-2702.2008.02482.x
[11]	Gramling R, Ingersoll LT, Anderson W,et al. End-of-life pref-erences,length-of-life conversations,and hospice enrollment in palliative care:a direct observation cohort study among people with advanced cancer[J]. J Palliat Med, 2019, 22(2):152-156. doi: 10.1089/jpm.2018.0476 pmid: 30526222
[12]	Cornish L. Holistic management of malignant wounds in palliative patients[J]. Br J Community Nurs, 2019, 24(9):S19-S23.
[13]	Probst S,Arber A,Faithfull S.Probst S,Arber A,Faithfull S. Malignant fungating wounds:the meaning of living in an unbounded body[J]. Eur J Oncol Nurs,2013, 17(1):38-45. doi: 10.1016/j.ejon.2012.02.001
[14]	Winardi A, Irwan AM. Topical treatment for controlling malignant wound odour[J]. Journal EWMA (JEWMA), 2019, 20 (2):7-13. doi: 10.35279/jewma201910.01
[15]	European Oncology Nursing Society(EONS). Recommendations for the care of patients with malignant fungating wounds(2015)[EB/OL].[2019-11-18]. https://www.cancernurse.eu/do-cuments/EONS Malignant Fungating Wounds.pdf
[16]	周帅, 江锦芳, 覃彦珠,等. 恶性肿瘤伤口症状管理的最佳证据总结[J]. 护理学杂志, 2020, 35(20):92-97.
	Zhou S, Jiang JF, Qin YZ,et al. Summary of best evidence regarding symptoms management of malignant fungating wounds[J]. J Nurs Sci, 2020, 35(20):92-97.